- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. (Pubmed Central) - Sep 15, 2023 The present study confirms that neoadjuvant FOLFIRINOX is associated with excellent survival and demonstrates that active smoking reduces its benefit. The nomogram can assist in daily clinical practice and emphasises the importance of smoking cessation in patients with PDAC, especially prior to NAT with FOLFIRINOX.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Journal, Metastases: Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement. (Pubmed Central) - Sep 15, 2023 Its combination with the immune checkpoint inhibitor durvalumab resulted in an efficiency improvement in the phase III setting...The evidence base for nanoliposomal irinotecan (Nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) is contradictory...These targeted agents are generally preferable to second-line chemotherapy. Broad molecular testing should be performed, preferably from tumor tissue, at the initiation of first-line therapy to timely identify potential molecular targets.
- |||||||||| irinotecan / Generic mfg.
Trial completion date, Trial primary completion date: XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study) (clinicaltrials.gov) - Sep 13, 2023 P=N/A, N=24, Recruiting, Trial completion date: Sep 2024 --> Mar 2024 Trial completion date: May 2023 --> Oct 2024 | Trial primary completion date: May 2023 --> Aug 2024
- |||||||||| Journal, Metastases: Age-related trends in the incidence of (Pubmed Central) - Sep 13, 2023
Trial completion date: Dec 2023 --> Jul 2024 A retrospective, observational study describing temporal trends in mCRC incidence and FOLFOXIRI treatment by age group using a nationwide database of commercially and Medicare Advantage-insured patients from 2010
- |||||||||| methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: High-Dose Methotrexate: Nursing Considerations for Administration and Supportive Care. (Pubmed Central) - Sep 11, 2023 Using existing and novel tools, nurses can closely monitor patients and provide supportive care to mitigate HDMTX toxicity. Early identification of delayed MTX elimination and subsequent treatment with glucarpidase, if appropriate, has been associated with shorter length of hospital stay and decreased incidence of grade 4 toxicities and mortality.
- |||||||||| BI 905711 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Sep 11, 2023 P1a/1b, N=13, Active, not recruiting, Early identification of delayed MTX elimination and subsequent treatment with glucarpidase, if appropriate, has been associated with shorter length of hospital stay and decreased incidence of grade 4 toxicities and mortality. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
P2 data, Journal, Metastases: First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. (Pubmed Central) - Sep 7, 2023 P2 Regorafenib can be safely combined with nivolumab and chemotherapy and showed promising activity in HER2-negative metastatic oesophagogastric cancer. A randomised, phase 3 clinical trial is planned.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Combination of Targeted Therapies for Colorectal Cancer Treatment. (Pubmed Central) - Sep 7, 2023 Here, we show that the combination of two targeted therapies, including bevacizumab (Bev), and a ?-glucuronidase-responsive albumin-binding prodrug of monomethyl auristatin E (MMAE), is efficient for the treatment of colorectal cancer implanted in mice...The increased anticancer efficacy is due to either a synergistic or an additive effect between Bev and MMAE selectively released from the glucuronide prodrug in the tumor microenvironment. Since numerous drug delivery systems such as antibody-drug conjugates employ MMAE as a cytotoxic payload, this finding may be of great interest for improving their therapeutic index by combining them with Bev, particularly for the therapy of colorectal cancer.
- |||||||||| Journal, Epigenetic controller: DNA methylation-associated allelic inactivation regulates Keratin 19 gene expression during pancreatic development and carcinogenesis. (Pubmed Central) - Sep 7, 2023
Since numerous drug delivery systems such as antibody-drug conjugates employ MMAE as a cytotoxic payload, this finding may be of great interest for improving their therapeutic index by combining them with Bev, particularly for the therapy of colorectal cancer. KRT19 protein was additionally detected in plasma of PDAC patients, with higher concentrations correlating with shorter progression-free survival in gemcitabine/nabPaclitaxel-treated and opposing trends in FOLFIRINOX-treated patients..
- |||||||||| NN1213 / Novo Nordisk
Biomarker, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Sep 7, 2023 P3, N=441, Recruiting, Trial completion date: Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026 Phase classification: P2/3 --> P3 | N=90 --> 441 | Trial completion date: Dec 2026 --> Dec 2034 | Trial primary completion date: Dec 2021 --> Dec 2027
- |||||||||| Enrollment closed, Trial completion date: Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma (clinicaltrials.gov) - Sep 6, 2023
P1, N=20, Active, not recruiting, Trial completion date: Jul 2023 --> Jun 2024 Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2026
- |||||||||| Vectibix (panitumumab) / Amgen, Takeda
Journal: Early-stage sigmoid colon cancer resection followed by liver metastasis recurrence 1 (Pubmed Central) - Aug 31, 2023 So, it is suggested that a complete blood count be checked after treatment in the follow-up of solid tumors. Even early-stage CRCs that have no pathological indications for additional resection have risks of metastases and recurrences, and we may need to consider that the criteria for additional resection should not be limited to pathological findings alone.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. (Pubmed Central) - Aug 30, 2023 In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.
|